Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. März 2026 09:34 ET | Quelle: Research and Markets

Antibody-drug Conjugates (ADCs) in Oncology Market Competitive Landscape Report 2026: Comprehensive Insights About 200+ Companies and 220+ Drugs by Product Type, Stage, and Route of Administration

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody-drug Conjugates (ADCs) in Oncology - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering.This report...
03. März 2026 06:38 ET | Quelle: Research and Markets

ADC Cytotoxic Payloads and Warheads Industry Research Report 2026-2035 - Breakthrough Cancer Therapies and Next-Generation ADC Innovations Accelerate Market Expansion

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "ADC Cytotoxic Payloads and Warheads Market (2nd Edition): Trends and Forecast Til 2035 - Distribution Type of Product, Type of Payload, Sub-Category...
23. Februar 2026 06:12 ET | Quelle: Research and Markets

Antibody-Drug Conjugate Drug Market Landscape Report 2026 Featuring 34 Key Players - Past and Emerging Trends, Partnership Opportunities, Drug Pipelines, and Leading Companies

Dublin, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugate Drug Landscape" report has been added to ResearchAndMarkets.com's offering.This report investigates the impacts and...
20. Februar 2026 10:56 ET | Quelle: Research and Markets

Glypican-3 (GPC3) Targeted Therapy Market Competitor Analysis Report 2026: More Than 20 Product Candidates are in Clinical Development and Further Eight at IND or IND-enabling Stage

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
20. Februar 2026 10:55 ET | Quelle: Research and Markets

PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2026: PYLARIFY Exceeds US$ 1 Billion in Net Sales and Became the First Ever Blockbuster Radiodiagnostic

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics" report has been added to ResearchAndMarkets.com's offering.This competitive...
19. Februar 2026 09:39 ET | Quelle: Research and Markets

Cancer & Antibody Conjugates Patent Landscape Analysis 2025: 3761 Patent Families - IP Trends, Including Time Evolution of Published Patents and Countries of Patent Filings

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Cancer & Antibody Conjugates Patent Landscape Analysis 2025" report has been added to ResearchAndMarkets.com's offering.Key Features: PDF >...
19. Februar 2026 07:33 ET | Quelle: Research and Markets

Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030 - Novartis' Pluvicto and Lutathera Have Catalyzed Commercial Momentum

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapeutics in Cancer Treatment: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for radioligand...
11. Februar 2026 08:05 ET | Quelle: VivoSim Labs, Inc.

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...
03. Februar 2026 07:53 ET | Quelle: Research and Markets

Antibody Drug Conjugates (ADC) Market Forecasts 2026-2030 with Executive and Consultant Guides - Fast-Tracking, Funding Availability, and Targeted Solutions Spurs Expansion

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Forecasts (2026-2030) by Cancer, Payload, Target, Product, User and Country/Region with Executive and Consultant...
29. Januar 2026 08:00 ET | Quelle: Breakthru Medicine

Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development

Breakthru Medicine emerges from stealth with $60M Series A in cancer drug development

Nächste Seite